Company Filing History:
16 out of 4,126 
3 out of 109 
2 out of 2,967 
Years Active: 1995-2022
Title: Alan D Attie: Innovator in Pharmaceutical Sciences from Madison, WI
Introduction
Alan D Attie is a prominent inventor based in Madison, Wisconsin, recognized for his significant contributions to the field of pharmaceutical sciences. With a remarkable portfolio of 16 patents, Attie's innovative spirit has led to advancements in treatments for various ailments, particularly in the realm of diabetes and cholesterol management.
Latest Patents
Two of Attie's latest patents showcase his dedication to addressing pressing health challenges. The first patent, titled "Benzoimidazole Indolyl Methanes and Methods of Using Them to Inhibit PCSK9 and PCSK9-Mediated Ailments," focuses on compounds that inhibit PCSK9, a protein involved in cholesterol metabolism. This invention outlines novel benzoimidazole indolyl methane compounds, pharmaceutical compositions containing these compounds, and their application in the treatment of PCSK9-mediated ailments.
The second patent, "Alpha/Beta-Polypeptide Analogs of Glucagon-Like Peptide 1," describes peptide analogs that maintain agonist activity and are more resistant to proteolytic degradation than their native counterparts. By replacing at least one α-amino acid in the native glucagon-like peptide 1 (GLP-1) with a β-amino acid residue, Attie's analogs offer promising therapeutic potential for diabetes management through their enhanced stability.
Career Highlights
Throughout his career, Alan D Attie has played a vital role in the scientific community, particularly during his tenure at reputable organizations such as the Wisconsin Alumni Research Foundation and Xenon Pharmaceuticals Inc. His work has not only advanced scientific understanding but also translated into practical applications that improve patient health outcomes.
Collaborations
Attie has collaborated with notable colleagues throughout his career, including Mark Gray-Keller and Mark Patrick Keller. These partnerships have fostered a collaborative environment that encourages innovation and drives forward the development of novel therapeutic solutions.
Conclusion
Alan D Attie's contributions to the field of pharmaceutical sciences have been pivotal in advancing the treatment options available for common health challenges. His innovative patents reflect a commitment to research and development that stands to benefit countless individuals affected by diseases such as diabetes and conditions mediated by cholesterol. As he continues to explore new frontiers in medicine, Attie's legacy as an inventor will undoubtedly pave the way for future advancements in health technology.